223 results about "Heart tissues" patented technology

The invention relates to a CACNA1A-based mental patient heart death intelligent identification system and method, the system comprises an immunohistochemical staining device, an image acquisition unit, an image analysis unit and an intelligent identification unit, the immunohistochemical staining device is used for performing CACNA1A immunohistochemical staining on formalin-fixed paraffin-embedded heart tissue slices; the image acquisition unit is used for shooting and obtaining a heart tissue CACNA1A immunohistochemical staining image; the image analysis unit is used for processing the heart tissue CACNA1A immunohistochemical staining image so as to determine a tissue staining region and image features thereof; and the intelligent identification unit outputs an identification prediction result of heart death of the mental patient according to the image features of the tissue staining region. Compared with the prior art, the mental patient heart death identification system can intelligently and accurately identify mental patient heart death.

Embodiments of methods and systems for determining electrocardiogram (ECG) depth of electrical activity. Electrical activity from a plurality of electrodes of a catheter is received; and within the electrical activity, an electrical signal originating from a depth within cardiac tissue is identified. In some embodiments, spatial electrode signal analysis of the electrical activity may be performed for each electrode of the plurality of electrodes. In some embodiments, a linear and / or non-linear combination of signal components within the electrical activity may be calculated. In some embodiments, a neural network may be provided with the electrical signals and may determine an estimated distance to the nearest activation for at least one of the plurality of electrodes. A visualization of the identified electrical signals at a specified depth within the cardiac tissue may be provided for display.

This disclosure relates to electro-anatomical mappings of cardiac tissue at different depths using a multi-electrode catheter. A multi-electrode catheter within a heart of a patient has a first plurality of electrodes on a first side and a second plurality of electrodes on a second side, wherein the first side is proximate to cardiac tissue at a first location and the second side is facing away from the cardiac tissue. Electrical activity is received from at least one electrode on the first side and the at least one electrode on the second side, and a signal analysis is performed thereon based at least in part on distances between electrodes on different sides of the multi-electrode catheter. The process is repeated for further locations of cardiac tissue in the heart, and an electro-anatomical map of the heart depicting electrical activity or scar tissue is generated based on the signal analysis.

Electro-anatomical mappings of cardiac tissue are created at different depths using a multi-electrode catheter that collects electrical activity from within a heart of a patient. A signal analysis of electrical activity at a first location is performed based on electrical activity received from a plurality of electrodes. A depth of electrical activity at the first location is determined in accordance with the signal analysis. This process is repeated for a plurality of further surface locations of cardiac tissue and at more than one depth. A plurality of electro-anatomical maps of the heart are generated, wherein the maps depict electrical activity at different depths of the cardiac tissue.

The application provides a sub-threshold heart communication method, system, device, medium and application, and belongs to the technical field of biomedical engineering. The method comprises the following steps: constructing a communication channel formed by coupling of multiple three-dimensional myocardial cell models; modulating physiological information into a sub-threshold electrical signal and injecting the signal into the channel for transmission; demodulating the signal at a receiving end to recover the information; wherein a physiological noise model is integrated in the channel to simulate a real physiological environment. The system corresponds to a transmitting end, a communication channel and a receiving end. The application adopts the sub-threshold heart communication method, system, device, medium and application, the three-dimensional myocardial cell model is used to more truly simulate a heart tissue structure, the complete communication process simulation of the sub-threshold electrical signal in a noise environment is realized for the first time, the existing research gap is filled, and an innovative technical platform is provided for research on cardiac electrophysiological mechanisms, performance optimization and evaluation of implantable medical devices such as a cardiac pacemaker.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention belongs to the technical field of medical information processing, and particularly discloses a regression model establishment method and system for detecting related indexes of myocardial cells of Wuzhishan pigs by using blood biochemical indexes, and the method comprises the following steps: collecting blood and heart tissue samples of the Wuzhishan pigs at different month ages, detecting the blood biochemical indexes including liver function, blood fat and blood sugar indexes, and establishing a regression model for detecting the related indexes of myocardial cells of the Wuzhishan pigs. Related indexes of myocardial cells; analyzing the index expression quantity difference, and screening significant difference indexes; then calculating the correlation between the remarkably different blood biochemical indexes and myocardial cell related indexes, and determining high-correlation blood biochemical indexes; and finally, constructing a first version of multiple regression model by respectively taking the myocardial enzyme index and the myocardial cell related index as dependent variables and the high-correlation blood biochemical index as an independent variable, removing outliers and updating the sample set on the basis of the first version of multiple regression model, and constructing a second version of multiple regression model by utilizing the new sample set, and on the basis of the second version of multiple regression model, constructing a third version of multiple regression model by adopting a stepwise regression method. According to the method, related indexes of myocardial cells can be accurately deduced through blood biochemical indexes, and support is provided for Wuzhishan pig heart disease research and model animal research and development.

To provide a system and method for generating, visualizing, and displaying cardiac signal information present at different depths in cardiac tissue. [Solution] Electroanatomical mapping of cardiac tissue is created at different depths using a multi-electrode catheter that collects electrical activity from within the patient's heart. Signal analysis of the electrical activity at a first location is performed based on the electrical activity received from multiple electrodes. The depth of the electrical activity at the first location is determined according to the signal analysis. This process is repeated at more than one depth for multiple further surface locations of the cardiac tissue. Multiple electroanatomical maps of the heart are generated, and the maps show the electrical activity at different depths of the cardiac tissue.

Provided herein are epicardium-derived paracrine factors for repairing heart tissue. In particular, provided herein are compositions and kits comprising epicardium-derived paracrine factors, such as hypoglycosylated follicular- stimulating hormone-like 1 (FSTL1), for treating and repairing damage to heart tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or heart growth defects, and methods of using the same.

Systems and methods for clustering wavefront signals in an electrophysiology map of cardiac tissue are provided. The systems and methods include receiving an electrophysiology map of the cardiac tissue, displaying propagation of the wavefront signals as a plurality of velocity vectors, discretizing the received electrophysiology map into a plurality of segments, clustering the velocity vectors into at least one group within each segment based on predefined criteria, and generating a trend line representing each group of clustered velocity vectors within each segment in the electrophysiology map.

A catheter deploys a flexible electrode that is at least partially made of preformed hydrogel to a target location in order to provide radiofrequency catheter ablation. The catheter stores the flexible electrode, which can be deployed and retracted. The preformed hydrogel is conductive and thus can provide an interface between a conductive metal wire and a target cardiac tissue. Electric energy is applied to the portions of the cardiac tissue target tissue that are the genesis of the errant and abnormal heartbeats via the flexible electrode. The electric energy may create lesions with lower risks of steam pops and tissue perforation.

A method includes s inserting, into a heart of a patient, a catheter having multiple electrodes, and placing the electrodes in contact with tissue of the heart. For each of the electrodes: (i) position signals indicative of a position of the electrode, and (ii) electrocardiogram (ECG) signals acquired by the electrode, are received during a predefined time interval. A positioning stability, along the predefined time interval, is calculated for each of the electrodes based on the position signals. For the electrodes whose positioning stability has an error smaller than a given threshold, calculating whether the ECG signals are indicative of an atrial fibrillation (AF) in the heart. The ECG signals that are indicative of the AF are stored.

The present invention provides novel capsid variants comprising a first amino acid sequence comprising the amino acid sequence RGDR (SEQ ID NO: 4286) or RGDY (SEQ ID NO: 4287) and a second amino acid sequence comprising the amino acid sequence RGD. These novel capsid variants de-target liver tissue and target muscle and heart tissue.

The therapeutic catheter is part of a system that includes a local impedance indicator displayed on a screen. The local impedance indicator displays relative changes in impedance to the user to quickly convey information that helps the user better understand where the catheter is positioned within the cardiac chamber.

A catheter for ablating cardiac tissue through irreversible electroporation, the catheter comprising a flexible circuit having a plurality of flex circuit branches and including an outwardly-facing ablation electrode including a plurality of ablation electrode branches extending proximally along a portion of a respective one of the flex circuit branches, and a support member having a plurality of support member branches, wherein the support member includes an electrically conductive base member covered by an electrically insulative coating, wherein each of the flex circuit branches is secured to a respective one of the support member branches, and the ablation electrode is electrically coupled to the electrically conductive base member.

The application provides a valve anchoring device, a guide device and a method for anchoring a prosthetic valve, mainly comprising an anchoring structure and a positioning member, wherein the anchoring structure has a first anchoring member and a second anchoring member extending from both sides of a combination member, the positioning member is connectable to the combination member, the combination member passes through a commissure of a leaflet of a heart tissue, the positioning member is positioned at one side of a heart atrioventricular valve adjacent to an atrium, the first anchoring member and the second anchoring member are positioned at one side of the heart atrioventricular valve adjacent to a ventricle, and the first anchoring member and the second anchoring member are cooperatively matched to anchor the prosthetic valve, so that the prosthetic valve is positioned relative to a native valve of the heart tissue. Therefore, the anchoring effect of the prosthetic valve can be improved.

The invention relates to the technical field of medical surgical instruments, in particular to a flexible multichannel heart mapping electrode for heart transfer and a construction method.The mapping electrode comprises a flexible substrate, a plurality of electrodes and a packaging layer, the flexible substrate is provided with a plurality of branches, the fixed ends of all the branches are connected with a common part, and the fixed ends of all the branches are connected with the packaging layer; the plurality of electrode arrays are arranged on one surface, in contact with the heart, of each branch and are used for measuring the potential of the heart, and the flexible substrate is made of a biocompatible flexible insulating material, so that each branch can be adsorbed by the surface tension of body fluid on the outer surface of the heart, the stimulation and damage to heart tissues are reduced, and the measurement accuracy is improved. Meanwhile, the electrode can be more accurately attached to the surface of the heart, the electric potential of the heart is accurately measured, and the mapping accuracy of the electrical activity of the heart is greatly improved.

The invention relates to the technical field of biological medicine, in particular to guanosine oxidation piRNA-014733, antisense nucleotide and application of the guanosine oxidation piRNA-014733 and the antisense nucleotide. The guanosine oxidation piRNA is named as o8G piRNA-014733, the guanosine oxidation piRNA is related to the regulation and control of myocardial ischemia reperfusion injury and myocardial cell ferroptosis, and the nucleotide sequence of the o8G piRNA-014733 gene is shown as SEQ ID NO. 1. The antisense nucleotide sequence of the o8G piRNA-014733 is as shown in SEQ ID NO. 2, and the antisense nucleotide sequence is as shown in SEQ ID NO. The expression of the o8G piRNA-014733 provided by the invention in heart tissues suffering from ischemia reperfusion injury and myocardial cells suffering from ferroptosis is remarkably up-regulated, and the o8G piRNA-014733 antisense nucleotide provided by the invention can be used for down-regulating the expression level of the o8G piRNA-014733 and inhibiting the ferroptosis of the myocardial cells.

A delivery system and method are described that include a catheter (102) and a stylet (200). The catheter (102) defines a delivery lumen (146) therethrough. The stylet (200) extends through the delivery lumen (146) of the catheter (102) and is movable relative to the catheter (102). The stylet (200) includes a tip section (220) at a distal end (212) of the stylet (200). The tip section (220) selectively transitions between a narrow state and a flared state. The tip section (220) in the flared state has a greater lateral extension than the tip section (220) in the narrow state. The tip section (220) in the narrow state is configured to project beyond a distal end (116) of the catheter (102) to pierce cardiac tissue. The tip section (220) is configured to transition from the narrow state to the flared state to anchor the stylet (200) to the cardiac tissue.

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

A transapical removal device that can be deployed in a catheter procedure to capture for removal or alteration a mitral valve clip or heart tissue, such as the anterior leaflet of the mitral valve, and methods of use are disclosed. The removal device includes a delivery catheter configured to be deployed near a mitral valve using a guide catheter. The delivery catheter has a snare head at the distal end, which assumes a collapsed state during movement of the delivery catheter through the guide catheter and deployed state for capturing a mitral valve clip or anterior leaflet. The snare head has one or more ablation delivery catheters configured to ablate tissue surrounding the pre-positioned mitral valve clip or anterior leaflet. In some arrangements within the scope of the present disclosure, the removal device includes a deployment mechanism for deploying a new transcatheter valve into the mitral valve.

The application relates to the field of medical devices, in particular to a positioning device of a valve repair system, which comprises a delivery catheter, a positioning device arranged in the delivery catheter, an anchoring mechanism, a flexible sleeve and a guide mechanism, the positioning device is arranged at the distal end of the delivery catheter, the positioning device is provided with a plurality of anchoring points distributed in the circumferential direction, the positioning device comprises a plurality of positioning units which are circumferentially distributed and connected with each other, wherein the positioning unit comprises a connecting part and a supporting part, the distal end of the supporting part is provided with two force arms, the two force arms intersect to form the anchoring point, and the included angle formed by the two force arms is greater than 90 DEG; the positioning device can meet the supporting rigidity required by clinical operation and can avoid damage to the heart tissue.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

The invention provides an artificial tricuspid valve forming ring with a perforated elastic inner core, belongs to the technical field of medical instruments, and can at least partially solve the problems that an existing tricuspid valve forming ring is poor in ring contraction effect; in order to solve the problem that the tricuspid valve plasty cannot achieve the plasty repair effect due to the facts that in the middle and long periods, the suturing position is torn, the stability is not enough, the risk of ring disengaging exists, and the tricuspid valve plasty cannot achieve the plasty repair effect, the tricuspid valve plasty patch comprises a supporting inner core, a coating layer, a fabric layer and a marker line. The supporting inner core is arranged, and due to the fact that a circle of 8-10 sets of suturing holes exist in the supporting inner core; the forming ring is used for suturing heart tissue during surgery, the ring contraction effect of the forming ring can be guaranteed to the maximum extent, and the risks of ring disengaging and the like caused by tearing of silica gel suturing edges and the like in the middle and later periods are effectively avoided.

To provide a system and method for generating, visualizing, and displaying cardiac signal information present at different depths in cardiac tissue. [Solution] Multiple signal mappings of cardiac tissue are created based on signals derived from different electrode sets of a multi-electrode catheter in the patient's heart. A first set of electrodes is selected, each located within a first distance of the selected electrodes, and a first spatial electrode signal analysis is performed on the electrical activity of the selected electrodes based on the signals from the first set of electrodes. A second set of electrodes is selected, each located within a second distance of the selected electrodes, and a second spatial electrode signal analysis is performed on the electrical activity of the selected electrodes based on the signals from the second set of electrodes. This process is repeated for multiple further locations within the heart and is used to generate at least a first and a second electroanatomical map of the heart.

The invention provides an immunosuppressive dendritic cell as well as a preparation method and application of the immunosuppressive dendritic cell, and belongs to the technical field of cell drugs. According to the dendritic cell of the over-expression CP-IL10-CAR fusion protein, CTLA4-Ig, PD-L1 and IL-10 with the amino acid sequences shown in SEQ ID NO: 17-19 are over-expressed in the dendritic cell, and a chimeric antigen receptor of a targeted fibroblast activation protein alpha (FAP) positive cell shown in SEQ ID NO: 20 is further expressed on the surface of the dendritic cell. The CP-IL10-CAR-dendritic cell medicine can be used for remarkably reducing the expression level of cardiac tissue fibrosis related protein caused by myocardial infarction, aortic arch constriction and myocardial ischemia reperfusion, regulating and controlling secretion of inflammatory factors, relieving the cardiac fibrosis degree and improving the cardiac function, and the dosage is small. Therefore, the invention provides a new means for preventing and treating heart fibrosis related diseases.

This invention provides a cardiac anchor and a corresponding cardiac anchoring system. The cardiac anchor includes a locking assembly and an anchoring member extending distally from the locking assembly. The anchoring member has a connecting end for engagement with cardiac tissue. The locking assembly includes a base and a suture clamping member, the suture clamping member being movably connected to the proximal end of the base. The distal end of the base has a bearing portion, and the suture clamping member has a suture clamping portion. A suture is disposed between the bearing portion and the suture clamping portion. The suture clamping member moves relative to the base to drive the suture clamping portion to move the suture toward the bearing portion and clamp the suture to the bearing portion. This cardiac anchor and cardiac anchoring system not only ensure endothelial overgrafting after the cardiac anchor is anchored to cardiac tissue, but also further avoids damage to the native chordae tendineae, ultimately greatly ensuring and maintaining the therapeutic effect of the surgery.

The devices and methods described herein may be used to restore left ventricular function to address mitral valve regurgitation. One variation of an implant comprises a plurality of tethered anchors and a plurality of force-distribution members slidably disposed on the tether between the anchors. One or more of the force-distribution members can comprise a bioabsorbable material. Methods comprise deploying the implant to cardiac tissue, cinching the implant to its hard stop (e.g., where further cinching does not cause further tissue tightening), providing a pre-selected amount of slack to the implant after it has been cinched to its hard stop configuration, and securing a lock member on the tether. Also disclosed herein are lock member deployment catheters that provide a pre-selected amount of tether slack as it secures a lock member on the tether.

A system for use in cardiac tissue includes an implant (160) and a delivery assembly (110) including a guide assembly (120) and a driver (116). The guide assembly has a distal portion transluminally advanceable into the heart while in a delivery state and includes (i) a guide frame (124) expandable within the heart toward an expanded state, (ii) guide rails (122), and (iii) a plurality of fasteners (140) tightenable within the heart from a proximal extracorporeal portion of the delivery assembly in a manner that draws the guide rails into a guide device around at least a portion of the guide frame. The driver is configured to advance the implant along the guide rails within the guide device. Other implementations are also described.